Cellular and molecular mechanisms of metformin: an overview
Open accessThe DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Abstract
Considerable efforts have been made since the 1950s to better understand the cellular and molecular mechanisms of action of metformin, a potent antihyperglycaemic agent now recommended as the first-line oral therapy for T2D (Type 2 diabetes). The main effect of this drug from the biguanide family is to acutely decrease hepatic glucose production, mostly through a mild and transient inhibition of the mitochondrial respiratory chain complex I. In addition, the resulting decrease in hepatic energy status activates AMPK (AMP-activated protein kinase), a cellular metabolic sensor, providing a generally accepted mechanism for the action of metformin on hepatic gluconeogenesis. The demonstration that respiratory chain complex I, but not AMPK, is the primary target of metformin was recently strengthened by showing that the metabolic effect of the drug is preserved in liver-specific AMPK-deficient mice. Beyond its effect on glucose metabolism, metformin has been reported to restore ovarian function in PCOS (polycystic ovary syndrome), reduce fatty liver, and to lower microvascular and macrovascular complications associated with T2D. Its use has also recently been suggested as an adjuvant treatment for cancer or gestational diabetes and for the prevention in pre-diabetic populations. These emerging new therapeutic areas for metformin will be reviewed together with recent findings from pharmacogenetic studies linking genetic variations to drug response, a promising new step towards personalized medicine in the treatment of T2D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In PCOS, metformin reduces insulin resistance and inhibits ovarian androgen production via effects on steroidogenic acute regulatory protein and 17alphahydroxylase (Diamanti-Kandarakis et al. , 2010; Viollet et al. , 2012).”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Viollet et al., 2012
The cited source says what the claim attributes to it.
In the citing paper
“a drug that is currently being used to treat type II diabetic patients, metformin [74], can activate AMPK”
From Senescence of T Lymphocytes: Implications for Enhancing Human Immunity (2016) · cites this paper as [74]
The cited source says what the claim attributes to it.
In the citing paper
“Given the evidence that metformin acts through the mitochondrial electron transport chain (ETC) by inhibiting complex I(46, 210–212) (Figure 8)”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [46]
In the citing paper
“By far the most important mechanism is the reduction in hepatic glucose production that is considered mediated by the activation of the global energy sensor in cells, adenosine monophosphate-activated protein kinase (AMPK) (Figure 1).(46)”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [46]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 4×
“Thus, AMPK activation by metformin induces the phosphorylation and inactivation of acetyl CoA carboxylase (ACC), an important rate-controlling enzyme for the synthesis of malonylCoA, which is both a critical precursor for the biosynthesis of fatty acids and a potent inhibitor of mitochondrial fatty acid oxidation [17].”
BackgroundInfluentialHyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“Furthermore, the authors found a doseresponse relationship between duration of exposure to metformin and cancer incidence [106].”
BackgroundGiovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950 · cited 25×
“Metformin most likely does not directly activate either LKB1 or AMPK as the drug does not influence the phosphorylation of AMPK by LKB1 in cell-free assay [21].”
BackgroundInfluentialLi, Y., Xu, S., Mihaylova, M. M., Zheng, B., Hou, X., Jiang, B., Park, O., Luo, Z., Lefai, E., Shyy, J. Y.-J., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.03.009 · Cited by 1,778
AMP-activated protein kinase induces a p53-dependent metabolic checkpoint
Jones, R. G., Plas, D. R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M. J., & Thompson, C. B. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.027 · Cited by 1,619
El-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399 · cited 2×
“In addition, it seems that mitochondrial action of metformin requires intact cells [22, 29, 30] and is prevented, at least in hepatocytes, neither by inhibition of nitric oxide synthase nor by various reactive oxygen species (ROS)”
BackgroundClinical pharmacokinetics of metformin
Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11534750-000000000-00000 · Cited by 1,318 · cited 8×
“Wang, Z.J., Yin, O.Q., Tomlinson, B., and Chow, M.S. (2008) OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine.”
BackgroundInfluentialMetformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291 · cited 2×
“Recently, data accumulated from case control studies [144] or the Metformin in Gestational Diabetes Trial [145] suggested that women treated with metformin had less weight gain and improved neonatal outcomes compared with those treated with insulin.”
ResultForetz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40671 · Cited by 1,181
Self-citationThe influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124
Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N., & Struhl, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2994 · Cited by 1,115 · cited 1×
“Breast 2 mg/ml Oral [138] Leukemia 250 mg/kg IP [124] Cancer stem cells 100 μg/ml IP [159] chemically-induced Breast 50-500 mg/kg Oral [160] Lung 250 mg/kg IP [161] Colon 250 mg/kg IP [162] Pancreas 320 mg/kg Oral [115] HER2/neu mice Breast 100 mg/kg Oral [118] PTEN mice All 300 mg/kg Oral [119] APC mice Gastrointesti…”
MethodMechanism by which metformin reduces glucose production in type 2 diabetes.
Hundal, R. S., Krssak, M., Dufour, S., Laurent, D., Lebon, V, Chandramouli, V, Inzucchi, S. E., Schumann, W. C., Petersen, K. F., Landau, B. R., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2063 · Cited by 1,052 · cited 1×
“production [8], mainly by inhibiting gluconeogenesis [9, 10].”
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
New Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996 · cited 1×
“neoplastic diseases and cancer mortality in T2D patients treated with metformin [107-109].”
BackgroundThe CREB coactivator TORC2 is a key regulator of fasting glucose metabolism
Koo, S.-H., Flechner, L., Qi, L., Zhang, X., Screaton, R. A., Jeffries, S., Hedrick, S., Xu, W., Boussouar, F., Brindle, P., et al. (2005) · Nature · doi:10.1038/nature03967 · Cited by 995
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action
Shu, Y., Sheardown, S. A., Brown, C., Owen, R. P., Zhang, S., Castro, R. A., Ianculescu, A. G., Yue, L., Lo, J. C., Burchard, E. G., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30558 · Cited by 967
Dowling, R. J. O., Zakikhani, M., Fantus, I. G., Pollak, M., & Sonenberg, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2310 · Cited by 933
Structure of mammalian AMPK and its regulation by ADP
Xiao, B., Sanders, M. J., Underwood, E., Heath, R., Mayer, F. V., Carmena, D., Jing, C., Walker, P. A., Eccleston, J. F., Haire, L. F., et al. (2011) · Nature · doi:10.1038/nature09932 · Cited by 926
Cool, B., Zinker, B., Chiou, W., Kifle, L., Cao, N., Perham, M., Dickinson, R., Adler, A., Gagne, G., Iyengar, R., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.05.005 · Cited by 925
Buzzai, M., Jones, R. G., Amaravadi, R. K., Lum, J. J., DeBerardinis, R. J., Zhao, F., Viollet, B., & Thompson, C. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4447 · Cited by 923
Self-citationMetformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner
Kalender, A., Selvaraj, A., Kim, S. Y., Gulati, P., Brûlé, S., Viollet, B., Kemp, B. E., Bardeesy, N., Dennis, P., Schlager, J. J., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.03.014 · Cited by 889
Self-citationSalminen, A., Hyttinen, J. M. T., & Kaarniranta, K. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0748-0 · Cited by 866
Sahra, I. B., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y., & Bost, F. (2008) · Oncogene · doi:10.1038/sj.onc.1211024 · Cited by 861
Use of Cells Expressing γ Subunit Variants to Identify Diverse Mechanisms of AMPK Activation
Hawley, S. A., Ross, F. A., Chevtzoff, C., Green, K. A., Evans, A., Fogarty, S., Towler, M. C., Brown, L. J., Ogunbayo, O. A., Evans, A. M., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.04.001 · Cited by 773 · cited 1×
“that increased cytosolic AMP indeed triggers the activation of the kinase by the drug [36].”
Tang, T., Lord, J. M., Norman, R. J., Yasmin, E., & Balen, A. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053.pub5 · Cited by 698
Metformin in non-alcoholic steatohepatitis.
Marchesini, G., Bianchi, G., Tomassetti, S., Zoli, M., & Melchionda, N. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06042-1 · Cited by 682
Metformin reverses fatty liver disease in obese, leptin-deficient mice.
Lin, H. Z., Yang, S. Q., Chuckaree, C., Kuhajda, F., Ronnet, G., & Diehl, A. M. (2000) · Nature Medicine · doi:10.1038/79697 · Cited by 673
Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1
Ben Sahra, I., Regazzetti, C., Robert, G., Laurent, K., Le Marchand-Brustel, Y., Auberger, P., Tanti, J.-F., Giorgetti-Peraldi, S., & Bost, F. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1769 · Cited by 616
AMPK is a direct adenylate charge-regulated protein kinase
Oakhill, J. S., Steel, R., Chen, Z.-P., Scott, J. W., Ling, N., Tam, S., & Kemp, B. E. (2011) · Science · doi:10.1126/science.1200094 · Cited by 612
Crosstalk between components of circadian and metabolic cycles in mammals
Asher, G., & Schibler, U. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.01.006 · Cited by 601
Antidiabetic Therapies Affect Risk of Pancreatic Cancer
Li, D., Yeung, S. J., Hassan, M. M., Konopleva, M., & Abbruzzese, J. L. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.013 · Cited by 584
Consensus on infertility treatment related to polycystic ovary syndrome
The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2008) · Human Reproduction · doi:10.1093/humrep/dem426 · Cited by 566
Ben Sahra, I., Laurent, K., Giuliano, S., Larbret, F., Ponzio, G., Gounon, P., Le Marchand-Brustel, Y., Giorgetti-Peraldi, S., Cormont, M., Bertolotto, C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2782 · Cited by 536
Thiazolidinediones, Like Metformin, Inhibit Respiratory Complex I
Brunmair, B., Staniek, K., Gras, F., Scharf, N., Althaym, A., Clara, R., Roden, M., Gnaiger, E., Nohl, H., Waldhäusl, W., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.4.1052 · Cited by 521
Kukidome, D., Nishikawa, T., Sonoda, K., Imoto, K., Fujisawa, K., Yano, M., Motoshima, H., Taguchi, T., Matsumura, T., & Araki, E. (2006) · Diabetes · doi:10.2337/diabetes.55.01.06.db05-0943 · Cited by 504
Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes
Landman, G. W. D., Kleefstra, N., van Hateren, K. J. J., Groenier, K. H., Gans, R. O. B., & Bilo, H. J. G. (2010) · Diabetes Care · doi:10.2337/dc09-1380 · Cited by 502
Metformin in cancer therapy: a new perspective for an old antidiabetic drug?
Ben Sahra, I., Le Marchand-Brustel, Y., Tanti, J.-F., & Bost, F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1186 · Cited by 493
Xie, Z., Lau, K., Eby, B., Lozano, P., He, C., Pennington, B., Li, H., Rathi, S., Dong, Y., Tian, R., et al. (2011) · Diabetes · doi:10.2337/db10-0351 · Cited by 490 · cited 1×
“Interestingly, treatment with metformin restored impaired autophagy in OVE26 diabetic mice and prevented heart damage in this model [87].”
BackgroundViollet, B., Guigas, B., Leclerc, J., Hébrard, S., Lantier, L., Mounier, R., Andreelli, F., & Foretz, M. (2009) · Acta Physiologica · doi:10.1111/j.1748-1716.2009.01970.x · Cited by 486
Self-citationA fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange
Liu, Y., Dentin, R., Chen, D., Hedrick, S., Ravnskjaer, K., Schenk, S., Milne, J., Meyers, D. J., Cole, P., III, J. Y., et al. (2008) · Nature · doi:10.1038/nature07349 · Cited by 484
He, L., Sabet, A., Djedjos, S., Miller, R., Sun, X., Hussain, M. A., Radovick, S., & Wondisford, F. E. (2009) · Cell · doi:10.1016/j.cell.2009.03.016 · Cited by 481
Hyperglycemia and Adverse Pregnancy Outcomes
Metzger, B. E., Lowe, L. P., Dyer, A. R., Trimble, E. R., Chaovarindr, U., Coustan, D. R., Hadden, D. R., McCance, D. R., Hod, M., McIntyre, H. D., et al. (2009) · Obstetric Anesthesia Digest · doi:10.1097/01.aoa.0000344706.95925.dc · Cited by 479
Tumours with PI3K activation are resistant to dietary restriction
Kalaany, N. Y., & Sabatini, D. M. (2009) · Nature · doi:10.1038/nature07782 · Cited by 468
Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer
Bodmer, M., Meier, C., Krähenbühl, S., Jick, S. S., & Meier, C. R. (2010) · Diabetes Care · doi:10.2337/dc09-1791 · Cited by 466
Cusi, K. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.11.4059 · Cited by 455
Zang, M., Zuccollo, A., Hou, X., Nagata, D., Walsh, K., Herscovitz, H., Brecher, P., Ruderman, N. B., & Cohen, R. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408149200 · Cited by 453
Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes
The GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group, & The Wellcome Trust Case Control Consortium 2 (2011) · Nature Genetics · doi:10.1038/ng.735 · Cited by 432
Palomba, S., Falbo, A., Zullo, F., & Orio, F. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0030 · Cited by 426
Mechanism for Fatty Acid “Sparing” Effect on Glucose-induced Transcription
Kawaguchi, T., Osatomi, K., Yamashita, H., Kabashima, T., & Uyeda, K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107895200 · Cited by 423
Gundewar, S., Calvert, J. W., Jha, S., Toedt-Pingel, I., Yong Ji, S., Nunez, D., Ramachandran, A., Anaya-Cisneros, M., Tian, R., & Lefer, D. J. (2009) · Circulation Research · doi:10.1161/circresaha.108.190918 · Cited by 423
Kim, Y. D., Park, K.-G., Lee, Y.-S., Park, Y.-Y., Kim, D.-K., Nedumaran, B., Jang, W. G., Cho, W.-J., Ha, J., Lee, I.-K., et al. (2008) · Diabetes · doi:10.2337/db07-0381 · Cited by 422
Johnson, J. A., Majumdar, S. R., Simpson, S. H., & Toth, E. L. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2244 · Cited by 421
Improved clinical outcomes associated with metformin in patients with diabetes and heart failure
Eurich, D. T., Majumdar, S. R., McAlister, F. A., Tsuyuki, R. T., & Johnson, J. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2345 · Cited by 419 · cited 1×
“12 combination with sulfonylurea reduced the mortality and the morbidity in T2D patients with heart failure in comparison of sulfonylurea monotherapy [82-84].”
BackgroundAccumulation of Metformin by Tissues of the Normal and Diabetic Mouse
Wilcock, C., & Bailey, C. J. (1994) · Xenobiotica · doi:10.3109/00498259409043220 · Cited by 418 · cited 1×
“to be higher than in other tissues, reaching hundreds of M in the periportal area [16].”
BackgroundMetformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis
Memmott, R. M., Mercado, J. R., Maier, C. R., Kawabata, S., Fox, S. D., & Dennis, P. A. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0055 · Cited by 408
Anisimov, V. N., Berstein, L. M., Egormin, P. A., Piskunova, T. S., Popovich, I. G., Zabezhinski, M. A., Kovalenko, I. G., Poroshina, T. E., Semenchenko, A. V., Provinciali, M., et al. (2005) · Experimental Gerontology · doi:10.1016/j.exger.2005.07.007 · Cited by 402
Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice
Huang, X., Wullschleger, S., Shpiro, N., McGuire, V. A., Sakamoto, K., Woods, Y. L., Mcburnie, W., Fleming, S., & Alessi, D. R. (2008) · Biochemical Journal · doi:10.1042/bj20080557 · Cited by 396
Metformin induces unique biological and molecular responses in triple negative breast cancer cells
Liu, B., Fan, Z., Edgerton, S. M., Deng, X.-S., Alimova, I. N., Lind, S. E., & Thor, A. D. (2009) · Cell Cycle · doi:10.4161/cc.8.13.8814 · Cited by 392
Foretz, M., Ancellin, N., Andreelli, F., Saintillan, Y., Grondin, P., Kahn, A., Thorens, B., Vaulont, S., & Viollet, B. (2005) · Diabetes · doi:10.2337/diabetes.54.5.1331 · Cited by 388
Self-citationMetformin: Taking away the candy for cancer?
Jalving, M., Gietema, J. A., Lefrandt, J. D., Jong, S. D., Reyners, A. K. L., Gans, R. O. B., & Vries, E. G. E. D. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.06.012 · Cited by 380
Natali, A., & Ferrannini, E. (2006) · Diabetologia · doi:10.1007/s00125-006-0141-7 · Cited by 377
Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial
Nair, S., Diehl, A. M., Wiseman, M., Farr, G. H., & Perrillo, R. P. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02025.x · Cited by 369 · cited 1×
“Evidence that metformin improved fatty liver disease by reversing hepatic steatosis in ob/ob mice [48, 49] and in rodents fed a high-fat diet [50] has been demonstrated but also reported in some clinical studies [51, 52].”
BackgroundLamanna, C., Monami, M., Marchionni, N., & Mannucci, E. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01349.x · Cited by 364
Roussel, R. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.409 · Cited by 361
Metformin is a Superior Substrate for Renal Organic Cation Transporter OCT2 rather than Hepatic OCT1
Kimura, N., Masuda, S., Tanihara, Y., Ueo, H., Okuda, M., Katsura, T., & Inui, K.-I. (2005) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.20.379 · Cited by 360
Tzvetkov, M. V., Vormfelde, S. V., Balen, D., Meineke, I., Schmidt, T., Sehrt, D., Sabolić, I., Koepsell, H., & Brockmöller, J. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.92 · Cited by 349
Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis
Takiar, V., Nishio, S., Seo-Mayer, P., King, J. D., Li, H., Zhang, L., Karihaloo, A., Hallows, K. R., Somlo, S., & Caplan, M. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011498108 · Cited by 345
Prevention of pancreatic cancer induction in hamsters by metformin
Schneider, M. B., Matsuzaki, H., Haorah, J., Ulrich, A., Standop, J., Ding, X., Adrian, T. E., & Pour, P. M. (2001) · Gastroenterology · doi:10.1053/gast.2001.23258 · Cited by 327
Hepatic Glucose Sensing via the CREB Coactivator CRTC2
Dentin, R., Hedrick, S., Xie, J., Yates, J., & Montminy, M. (2008) · Science · doi:10.1126/science.1151363 · Cited by 319
Kisfalvi, K., Eibl, G., Sinnett-Smith, J., & Rozengurt, E. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0418 · Cited by 315
Cardiovascular Outcomes in Trials of Oral Diabetes Medications: A Systematic Review
Selvin, E., Bolen, S., Yeh, H.-C., Wiley, C., Wilson, L. M., Marinopoulos, S. S., Feldman, L., Vassy, J., Wilson, R., Bass, E. B., et al. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.19.2070 · Cited by 300
Maida, A., Lamont, B. J., Cao, X., & Drucker, D. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1937-z · Cited by 294
Metformin Prevents Progression of Heart Failure in Dogs: Role of AMP-Activated Protein Kinase
Sasaki, H., Asanuma, H., Fujita, M., Takahama, H., Wakeno, M., Ito, S., Ogai, A., Asakura, M., Kim, J., Minamino, T., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.798561 · Cited by 289
Stephenne, X., Foretz, M., Taleux, N., van der Zon, G. C., Sokal, E., Hue, L., Viollet, B., & Guigas, B. (2011) · Diabetologia · doi:10.1007/s00125-011-2311-5 · Cited by 287
Self-citationMetformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway
Morales, A. I., Detaille, D., Prieto, M., Puente, A., Briones, E., Arévalo, M., Leverve, X., López-Novoa, J. M., & El-Mir, M.-Y. (2010) · Kidney International · doi:10.1038/ki.2010.11 · Cited by 284
OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine
Wang, Z.-J., Yin, O. Q. P., Tomlinson, B., & Chow, M. S. S. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328302cd41 · Cited by 281
Batandier, C., Guigas, B., Detaille, D., El-Mir, M., Fontaine, E., Rigoulet, M., & Leverve, X. M. (2006) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-006-9003-8 · Cited by 279
Self-citationWright, J. L., & Stanford, J. L. (2009) · Cancer Causes & Control · doi:10.1007/s10552-009-9407-y · Cited by 276
In vitro metformin anti-neoplastic activity in epithelial ovarian cancer
Gotlieb, W. H., Saumet, J., Beauchamp, M.-C., Gu, J., Lau, S., Pollak, M. N., & Bruchim, I. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.04.008 · Cited by 267
Detaille, D., Guigas, B., Chauvin, C., Batandier, C., Fontaine, E., Wiernsperger, N., & Leverve, X. (2005) · Diabetes · doi:10.2337/diabetes.54.7.2179 · Cited by 263
Self-citationForetz, M., Carling, D., Guichard, C., Ferré, P., & Foufelle, F. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.24.14767 · Cited by 256
Self-citationXiang, X., Saha, A. K., Wen, R., Ruderman, N. B., & Luo, Z. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.06.133 · Cited by 251
Vazquez-Martin, A., Oliveras-Ferraros, C., & Menendez, J. A. (2009) · Cell Cycle · doi:10.4161/cc.8.1.7499 · Cited by 250
Zhuang, Y., & Miskimins, W. K. (2008) · Journal of Molecular Signaling · doi:10.1186/1750-2187-3-18 · Cited by 246
Um, J. H., Yang, S., Yamazaki, S., Kang, H., Viollet, B., Foretz, M., & Chung, J. H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.c700070200 · Cited by 244
Self-citationEl-Mir, M.-Y., Detaille, D., R-Villanueva, G., Delgado-Esteban, M., Guigas, B., Attia, S., Fontaine, E., Almeida, A., & Leverve, X. (2008) · Journal of Molecular Neuroscience · doi:10.1007/s12031-007-9002-1 · Cited by 244
Self-citationGunton, J. E., Delhanty, P. J. D., Takahashi, S.-I., & Baxter, R. C. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021394 · Cited by 234
Insulin-Lowering Effects of Metformin in Women with Early Breast Cancer
Goodwin, P. J., Pritchard, K. I., Ennis, M., Clemons, M., Graham, M., & Fantus, I. G. (2008) · Clinical Breast Cancer · doi:10.3816/cbc.2008.n.060 · Cited by 228
DE JAGER, J., KOOY, A., LEHERT, P., BETS, D., WULFFELÉ, M. G., TEERLINK, T., SCHEFFER, P. G., SCHALKWIJK, C. G., DONKER, A. J. M., & STEHOUWER, C. D. A. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01420.x · Cited by 220
Hong, Y. H., Varanasi, U. S., Yang, W., & Leff, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304112200 · Cited by 220 · cited 1×
“element binding protein (ChREBP) and hepatocyte nuclear factor 4 (HNF4)) and coactivators (p300) [54-59].”
BackgroundCufí, S., Vazquez-Martin, A., Oliveras-Ferraros, C., Martin-Castillo, B., Joven, J., & Menendez, J. A. (2010) · Cell Cycle · doi:10.4161/cc.9.22.14048 · Cited by 216 · cited 1×
“mesenchymal transition (EMT), a key event in the development of the tubulointerstitial fibrosis during the diabetic nephropathy [64].”
BackgroundDual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis
Isakovic, A., Harhaji, L., Stevanovic, D., Markovic, Z., Sumarac-Dumanovic, M., Starcevic, V., Micic, D., & Trajkovic, V. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7080-4 · Cited by 204
Metformin Decreases Intracellular Production of Reactive Oxygen Species in Aortic Endothelial Cells
Ouslimani, N., Peynet, J., Bonnefont-Rousselot, D., Thérond, P., Legrand, A., & Beaudeux, J.-L. (2005) · Metabolism · doi:10.1016/j.metabol.2005.01.029 · Cited by 204 · cited 1×
“inhibiting both NAD(P)H oxidase and the respiratory-chain complex 1 [93].”
BackgroundRegulation of Transcription by AMP-activated Protein Kinase
Yang, W., Hong, Y. H., Shen, X.-Q., Frankowski, C., Camp, H. S., & Leff, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100316200 · Cited by 200
Green, A. S., Chapuis, N., Trovati Maciel, T., Willems, L., Lambert, M., Arnoult, C., Boyer, O., Bardet, V., Park, S., Foretz, M., et al. (2010) · Blood · doi:10.1182/blood-2010-02-269837 · Cited by 199
Self-citationMetformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5
Caton, P. W., Nayuni, N. K., Kieswich, J., Khan, N. Q., Yaqoob, M. M., & Corder, R. (2010) · Journal of Endocrinology · doi:10.1677/joe-09-0345 · Cited by 198
Metformin suppresses intestinal polyp growth in Apc Min/+ mice
Tomimoto, A., Endo, H., Sugiyama, M., Fujisawa, T., Hosono, K., Takahashi, H., Nakajima, N., Nagashima, Y., Wada, K., Nakagama, H., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00933.x · Cited by 185
Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth
Algire, C., Zakikhani, M., Blouin, M.-J., Shuai, J. H., & Pollak, M. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0038 · Cited by 185
Zhou, K., Donnelly, L. A., Kimber, C. H., Donnan, P. T., Doney, A. S. F., Leese, G., Hattersley, A. T., McCarthy, M. I., Morris, A. D., Palmer, C. N. A., et al. (2009) · Diabetes · doi:10.2337/db08-0896 · Cited by 184
Algire, C., Amrein, L., Bazile, M., David, S., Zakikhani, M., & Pollak, M. (2011) · Oncogene · doi:10.1038/onc.2010.483 · Cited by 181
Hosono, K., Endo, H., Takahashi, H., Sugiyama, M., Uchiyama, T., Suzuki, K., Nozaki, Y., Yoneda, K., Fujita, K., Yoneda, M., et al. (2010) · Molecular Carcinogenesis · doi:10.1002/mc.20637 · Cited by 177
Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure
Yin, M., van der Horst, I. C. C., van Melle, J. P., Qian, C., van Gilst, W. H., Silljé, H. H. W., & de Boer, R. A. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00054.2011 · Cited by 170
Tubular Injury in a Rat Model of Type 2 Diabetes Is Prevented by Metformin
Takiyama, Y., Harumi, T., Watanabe, J., Fujita, Y., Honjo, J., Shimizu, N., Makino, Y., & Haneda, M. (2011) · Diabetes · doi:10.2337/db10-0655 · Cited by 169
Bowker, S. L., Yasui, Y., Veugelers, P., & Johnson, J. A. (2010) · Diabetologia · doi:10.1007/s00125-010-1750-8 · Cited by 165
Lee, J.-M., Seo, W.-Y., Song, K.-H., Chanda, D., Kim, Y. D., Kim, D.-K., Lee, M.-W., Ryu, D., Kim, Y.-H., Noh, J.-R., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.134890 · Cited by 162
An energetic tale of AMPK-independent effects of metformin
Miller, R. A., & Birnbaum, M. J. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43661 · Cited by 162
Johnson, J. A., Simpson, S. H., Toth, E. L., & Majumdar, S. R. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01448.x · Cited by 161 · cited 1×
“This conclusion has been replicated in other clinical or epidemiological studies [73, 74].”
ResultARGAUD, D., ROTH, H., WIERNSPERGER, N., & LEVERVE, X. M. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17886.x · Cited by 152
Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation
Rahbar, S., Natarajan, R. D., Yerneni, K. K. V., Scott, S., Gonzales, N., & Nadler, J. L. (2000) · Clinica Chimica Acta · doi:10.1016/s0009-8981(00)00327-2 · Cited by 152
Metformin induces suppression of NAD(P)H oxidase activity in podocytes
Piwkowska, A., Rogacka, D., Jankowski, M., Dominiczak, M. H., Stępiński, J., & Angielski, S. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.01.119 · Cited by 150
GUIGAS, B., DETAILLE, D., CHAUVIN, C., BATANDIER, C., De OLIVEIRA, F., FONTAINE, E., & LEVERVE, X. (2004) · Biochemical Journal · doi:10.1042/bj20040885 · Cited by 150
Self-citationMacDonald, M. R., Eurich, D. T., Majumdar, S. R., Lewsey, J. D., Bhagra, S., Jhund, P. S., Petrie, M. C., McMurray, J. J. V., Petrie, J. R., & McAlister, F. A. (2010) · Diabetes Care · doi:10.2337/dc09-2227 · Cited by 149
Leclerc, I., Lenzner, C., Gourdon, L., Vaulont, S., Kahn, A., & Viollet, B. (2001) · Diabetes · doi:10.2337/diabetes.50.7.1515 · Cited by 148
Self-citationBalani, J., Hyer, S. L., Rodin, D. A., & Shehata, H. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02780.x · Cited by 145
Hurst, R. T., & Lee, R. W. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-10-200311180-00010 · Cited by 139
The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients
Ersoy, C., Kiyici, S. K., Budak, F., Oral, H. B., Güçlü, M., Duran, C., Selimoğlu, H., Ertürk, E., Tuncel, E., & İmamoğlu, Ş. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.02.006 · Cited by 132
Frid, A., Sterner, G. N., Löndahl, M., Wiklander, C., Cato, A., Vinge, E., & Andersson, A. (2010) · Diabetes Care · doi:10.2337/dc09-1284 · Cited by 126
AMP‐ACTIVATED PROTEIN KINASE ACTIVATION AS A STRATEGY FOR PROTECTING VASCULAR ENDOTHELIAL FUNCTION
Zou, M., & Wu, Y. (2008) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2007.04851.x · Cited by 115
Schulz, E., Anter, E., Zou, M.-H., & Keaney, J. F. (2005) · Circulation · doi:10.1161/circulationaha.105.546812 · Cited by 114
Effects of Metformin on Lactate Uptake and Gluconeogenesis in the Perfused Rat Liver
Radziuk, J., Zhang, Z., Wiernsperger, N., & Pye, S. (1997) · Diabetes · doi:10.2337/diab.46.9.1406 · Cited by 113
Neither LKB1 Nor AMPK Are the Direct Targets of Metformin
Hardie, D. G. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.07.032 · Cited by 113
Role of KLF15 in Regulation of Hepatic Gluconeogenesis and Metformin Action
Takashima, M., Ogawa, W., Hayashi, K., Inoue, H., Kinoshita, S., Okamoto, Y., Sakaue, H., Wataoka, Y., Emi, A., Senga, Y., et al. (2010) · Diabetes · doi:10.2337/db09-1679 · Cited by 112
Zhuang, Y., & Miskimins, W. K. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0343 · Cited by 109
Pharmacogenetics of Anti-Diabetes Drugs
DiStefano, J. K., & Watanabe, R. M. (2010) · Pharmaceuticals · doi:10.3390/ph3082610 · Cited by 107
Mithieux, G., Guignot, L., Bordet, J.-C., & Wiernsperger, N. (2002) · Diabetes · doi:10.2337/diabetes.51.1.139 · Cited by 103
Legro, R. S., Barnhart, H. X., Schlaff, W. D., Carr, B. R., Diamond, M. P., Carson, S. A., Steinkampf, M. P., Coutifaris, C., McGovern, P. G., Cataldo, N. A., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1736 · Cited by 102
Tang, T., Lord, J. M., Norman, R. J., Yasmin, E., & Balen, A. H. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053.pub4 · Cited by 101
Détaille, D., Guigas, B., Leverve, X. M., Wiernsperger, N. F., & Devos, P. E. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)00858-4 · Cited by 100
Self-citationKane, D. A., Anderson, E. J., Price, J. W., Woodlief, T. L., Lin, C.-T., Bikman, B. T., Cortright, R. N., & Neufer, P. D. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.06.022 · Cited by 99
Nitric Oxide, NAD(P)H Oxidase, and Atherosclerosis
Muller, G., & Morawietz, H. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2403 · Cited by 97
Metformin: The Safest Hypoglycaemic Agent in Chronic Kidney Disease?
Nye, H. J., & Herrington, W. G. (2011) · Nephron Clinical Practice · doi:10.1159/000323739 · Cited by 92
Zhang, C., Pan, S., Meng, R., Peng, C., Xiong, Z., Chen, B., Chen, G., Yao, F., Chen, Y., Ma, Y., et al. (2011) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2010.05461.x · Cited by 91
Kim, E., Liu, N.-C., Yu, I.-C., Lin, H.-Y., Lee, Y.-F., Sparks, J. D., Chen, L.-M., & Chang, C. (2011) · Diabetes · doi:10.2337/db10-0393 · Cited by 87
Pantalone, K. M., Kattan, M. W., Yu, C., Wells, B. J., Arrigain, S., Jain, A., Atreja, A., & Zimmerman, R. S. (2010) · Diabetes Care · doi:10.2337/dc10-0017 · Cited by 86
Tosca, L., Solnais, P., Ferré, P., Foufelle, F., & Dupont, J. (2006) · Biology of Reproduction · doi:10.1095/biolreprod.106.050831 · Cited by 86
Metformin Versus Insulin for the Treatment of Gestational Diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2009) · Obstetric Anesthesia Digest · doi:10.1097/01.aoa.0000344705.95925.07 · Cited by 85
Hinke, S. A., Martens, G. A., Cai, Y., Finsi, J., Heimberg, H., Pipeleers, D., & Van de Casteele, M. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707189 · Cited by 77
Metformin inhibits inflammatory angiogenesis in a murine sponge model
Xavier, D. O., Amaral, L. S. D. B., Gomes, M. A., Rocha, M. A., Campos, P. R., Cota, B. D. C. V., Tafuri, L., Paiva, A., Silva, J. H., Andrade, S. P., et al. (2009) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2009.08.004 · Cited by 71
Review: Metformin: Potential benefits and use in chronic kidney disease
PILMORE, H. L. (2010) · Nephrology · doi:10.1111/j.1440-1797.2010.01328.x · Cited by 69
Metformin: safety in cardiac patients
Khurana, R., & Malik, I. S. (2010) · Postgraduate Medical Journal · doi:10.1136/hrt.2009.173773 · Cited by 68
Scolletta, S., & Biagioli, B. (2009) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2009.10.002 · Cited by 65
Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance
Adler, A. I., Shaw, E. J., Stokes, T., Ruiz, F., & on behalf of the Guideline Development Group (2009) · BMJ · doi:10.1136/bmj.b1668 · Cited by 63
Large, V, & Beylot, M. (1999) · Diabetes · doi:10.2337/diabetes.48.6.1251 · Cited by 60
Umehara, K., Iwatsubo, T., Noguchi, K., & Kamimura, H. (2007) · Xenobiotica · doi:10.1080/00498250701546012 · Cited by 60
Yeh, C.-H., Chen, T.-P., Wang, Y.-C., Lin, Y.-M., & Fang, S.-W. (2010) · Mediators of Inflammation · doi:10.1155/2010/130636 · Cited by 59
Action of metformin on erythrocyte membrane fluidity in vitro and in vivo
Muller, S., Denet, S., Candiloros, H., Barrois, R., Wiernsperger, N. F., Donner, M., & Drouin, P. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01287-9 · Cited by 57
He, G., Sung, Y. M., DiGiovanni, J., & Fischer, S. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3111 · Cited by 55
Grisouard, J., Dembinski, K., Mayer, D., Keller, U. B., Müller-Stich, B. P., & Christ‐Crain, M. (2011) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-3-16 · Cited by 55
Benes, J., Kazdova, L., Drahota, Z., Houstek, J., Medrikova, D., Kopecky, J., Kovarova, N., Vrbacky, M., Sedmera, D., Strnad, H., et al. (2011) · Clinical Science · doi:10.1042/cs20100527 · Cited by 51
Raso, G. M., Esposito, E., Iacono, A., Pacilio, M., Cuzzocrea, S., Canani, R. B., Calignano, A., & Meli, R. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.12.013 · Cited by 46
Кравчук, Е. Н., Grineva, E. N., Bairamov, A. A., Galagudza, M. M., & Vlasov, T. D. (2011) · Experimental Diabetes Research · doi:10.1155/2011/907496 · Cited by 46
Metformin in chemically-induced mammary carcinogenesis in rats
Bojkova, B., Orendas, P., Garajova, M., Kassayova, M., Kutna, V., Ahlersova, E., & Ahlers, I. (2009) · Neoplasma · doi:10.4149/neo_2009_03_269 · Cited by 40
Insulin and metformin may prevent renal injury in young type 2 diabetic Goto–Kakizaki rats
Louro, T. M., Matafome, P. N., Nunes, E., da Cunha, F. X., & Seiça, R. M. F. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.11.029 · Cited by 32
Khurana, R., & Malik, I. S. (2009) · Cited by 28
Optimizing Cardiac Fatty Acid and Glucose Metabolism as an Approach to Treating Heart Failure
Lopaschuk, G. D. (2006) · Seminars in Cardiothoracic and Vascular Anesthesia · doi:10.1177/1089253206291150 · Cited by 27
The effects of glucose, insulin and metformin on the order parameters of isolated red cell membranes
Freisleben, H., Ruckert, S., Wiernsperger, N. F., & Zimmer, G. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90491-z · Cited by 25
Schäfer, H., Mainka, L., Rathgeber, G., & Zimmer, G. (1983) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(83)90366-2 · Cited by 19
[Effect of fenofibrate and metformin on lipotoxicity in OLETF rat kidney].
Wang, W., Guo, X., Wu, H., Wang, N.-H., & Xu, X.-S. (2006) · PubMed · Cited by 11
Wrongfully accused: metformin use in heart failure
Eurich, D. T., & McAlister, F. A. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.186 · Cited by 5
Metformin and the AMP-activated protein kinase
Guigas, B., & Hue, L. (2008) · DIAL (Catholic University of Leuven) · Cited by 1
Self-citation
Cited by
Kinaan, M., Ding, H., & Triggle, C. R. (2015) · Medical Principles and Practice · doi:10.1159/000381643 · Cited by 1,515
Metformin: from mechanisms of action to therapies
Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.018 · Cited by 1,501
Self-citationClinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management
Chaudhury, A., Duvoor, C., Reddy Dendi, V. S., Kraleti, S., Chada, A., Ravilla, R., Marco, A., Shekhawat, N. S., Montales, M. T., Kuriakose, K., et al. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00006 · Cited by 1,500
Durham, A. L., Speer, M. Y., Scatena, M., Giachelli, C. M., & Shanahan, C. M. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy010 · Cited by 1,093
Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis
Wheaton, W. W., Weinberg, S. E., Hamanaka, R. B., Soberanes, S., Sullivan, L. B., Anso, E., Glasauer, A., Dufour, E., Mutlu, G. M., Budigner, G. S., et al. (2014) · eLife · doi:10.7554/elife.02242 · Cited by 1,105
“Metformin suppresses liver gluconeogenesis thereby reducing glucose release from the liver (Inzucchi et al., 1998; Viollet et al., 2012).”
Metadata
- Authors
- Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F.
- Affiliations
- INSERM, U1016, Institut Cochin, Paris, France
- Leiden University Medical Center (NL)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Leclerc, Jocelyne
- Foretz, Marc
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2011-11-11
- Volume
- 122
- Issue
- 6
- Pages
- 253-270
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- PMC
- PMC3398862
- OpenAlex
- W2154024784
- Cited by
- 1,720
- References
- 167
- Citations by year
- 2026: 63 · 2025: 85 · 2024: 96 · 2023: 103 · 2022: 106 · 2021: 143 · 2020: 155 · 2019: 135 · 2018: 141 · 2017: 156 · 2016: 137 · 2015: 144 · 2014: 117 · 2013: 104 · 2012: 34
- FWCI
- 7.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Keywords
- metformin, type 2 diabetes, biguanides, AMPK, mitochondrial complex I inhibition, hepatic gluconeogenesis, hepatic glucose production, polycystic ovary syndrome, hepatic steatosis, diabetes complications, adjuvant cancer therapy, gestational diabetes mellitus, prediabetes, pharmacogenetics, personalized medicine
- MeSH terms
- Animals, Cardiovascular System, Diabetic Nephropathies, Female, Humans, Hypoglycemic Agents, Metformin, Neoplasms, Polycystic Ovary Syndrome, Circadian Clocks
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.